Effect of quadrivalent human papillomavirus vaccination on oral squamous cell papillomas

JAMA Dermatology

Volumn 151, Issue 12, 2015, Pages 1359-1363

  Cyrus, Nika ^a   Blechman, Adam B ^b   LeBoeuf, Matthew ^c   Belyaeva, Elizaveta A ^d   De Koning, Maurits N C ^e   Quint, Koen D ^e,f   Stern, John J ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d PENNSYLVANIA HOSPITAL   (United States)

^e Manager Development and Diagnostic Services (DDS)   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CASE REPORT; CHEEK MUCOSA; CHRONIC DISEASE; CROSS PROTECTION; DISEASE CLEARANCE; DNA SEQUENCE; DRUG EFFECT; FOLLOW UP; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 32; HUMAN TISSUE; IMMUNOCOMPETENCE; LASER CAPTURE MICRODISSECTION; LIP DISEASE; MALE; MOUTH TUMOR; NONHUMAN; ORAL BIOPSY; PAPILLOMA; PAPILLOMAVIRUS INFECTION; PAPULE; PRIORITY JOURNAL; RECURRENT DISEASE; SQUAMOUS CELL PAPILLOMA; TONGUE DISEASE; TREATMENT DURATION; VACCINATION; WART VIRUS;

EID: 84949633897     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.2805     Document Type: Article

References (15)

1. Kwok CS, Gibbs S, Bennett C, Holland R, Abbott R. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2012;9:CD001781.
2. Stanley M. Immune responses to human papillomavirus. vaccine. 2006;24(suppl 1):S16-S22.
3. Venugopal SS, Murrell DF. Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man. Arch Dermatol. 2010;146(5): 475-477.
4. Daniel BS, Murrell DF. Complete resolution of chronic multiple verruca vulgaris treated with quadrivalent human papillomavirus vaccine. JAMA Dermatol. 2013;149(3):370-372.
5. Kreuter A,Waterboer T, Wieland U. Regression of cutaneous warts in a patient with WILD syndrome following recombinant quadrivalent human papillomavirus vaccination. Arch Dermatol. 2010;146(10):1196-1197.
6. Landis MN, Lookingbill DP, Sluzevich JC. Recalcitrant plantar warts treated with recombinant quadrivalent human papillomavirus vaccine. J Am Acad Dermatol. 2012;67(2):e73-e74.
7. Silling S,Wieland U,Werner M, Pfister H, Potthoff A, Kreuter A. Resolution of novel human papillomavirus-induced warts after HPV vaccination. Emerg Infect Dis. 2014;20(1):142-145.
8. de Koning MN, ter Schegget J, Eekhof JA, et al. Evaluation of a novel broad-spectrum PCR-multiplex genotyping assay for identification of cutaneous wart-associated human papillomavirus types. J Clin Microbiol. 2010;48(5): 1706-1711.
9. Kreuter A, Wieland U. Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients. J AmAcad Dermatol. 2013;68(1):179-180.
10. Bruggink SC, de Koning MN, Gussekloo J, et al. Cutaneous wart-associated HPV types: prevalence and relation with patient characteristics. J Clin Virol. 2012;55(3):250-255.
11. Chang F, Syrjinen S, Kellokoski J, Syrjinen K. Human papillomavirus (HPV) infections and their associations with oral disease. J Oral Pathol Med. 1991;20(7):305-317.
12. Weinberg A, Song LY, Saah A, et al; IMPAACT/PACTG P1047 Team. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis. 2012;206(8): 1309-1318.
13. Szarewski A, Skinner SR, Garland SM, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 2013; 208(9):1391-1396.
14. Wheeler CM, Castellsagu X, Garland SM, et al; HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13 (1):100-110.
15. Kumar P, Dar L, Saldiwal S, et al. Intralesional injection ofMycobacterium w vaccine vs imiquimod, 5%, cream in patients with anogenital warts: a randomized clinical trial. JAMA Dermatol. 2014;150(10):1072-1078.